Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to bisphosphonates

Journal of Thoracic Oncology

Volumn 4, Issue 2, 2009, Pages 260-262

  Mauricio Dr , Obondent ^a   Francis, Lisa ^a   Athar Dr , Uzma ^a   Shah Dr , Chirag ^a   Chaudhary Dr , Madhuchhanda ^a   Gajra Dr , Ajeet ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Bisphosphonates; Hypertrophic osteoarthropathy; Lung cancer

Indexed keywords

ANTIBIOTIC AGENT; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; BONE SCINTISCANNING; CASE REPORT; CELLULITIS; CLUBBING FINGERS; ERYTHEMA; FEVER; HUMAN; HYPERTROPHIC OSTEOARTHROPATHY; LEG PAIN; LEG SWELLING; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; DIFFERENTIAL DIAGNOSIS; LEG; OSTEOARTHROPATHY;

ADULT; BONE DENSITY CONSERVATION AGENTS; CELLULITIS; DIAGNOSIS, DIFFERENTIAL; DIPHOSPHONATES; HUMANS; LOWER EXTREMITY; MALE; OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC; TREATMENT OUTCOME;

EID: 65649091370     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181952915     Document Type: Article

References (10)

1. Martínez-Lavín M, Matucci-Cerinic M, Jajic I, Pineda C. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol 1993;20:1386-1387.
2. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest 1998;114:1535-1537.
3. Kozak KR, Milne GL, Morrow JD, Cuiffo BP. Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase- 2-derived prostaglandin E2. Nat Clin Pract Rheumatol 2006;2:452-456.
4. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol 2004;203:721-728.
5. Altman RD, Tenenbaum J. Hypertrophic osteoarthopathy. In Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS, Kelley WN. (Eds.), Kelley's Textbook of Rheumatology, 6th Ed. Philadelphia: Saunders, 2001. Pp. 1589-1594.
6. Albrecht S, Keller A. Postchemotherapeutic reversibility of hypertrophic osteoarthropathy in a patient with bronchogenic adenocarcinoma. Clin Nucl Med 2003;28:463-466.
7. Reid IR. Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 2003;15:458-463.
8. Garske LA, Bell SC. Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest 2002;121: 1363-1364.
9. Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004;23:330-332.
10. Speden D, Nicklason F, Francis H, Ward J. The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA). Aust N Z J Med 1997;27:307-310